AGEN
AGENUS INC
NASDAQ · Healthcare · Biotechnology · US
$7.85
+8.73%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$7.60
From 52W high−6.10%
Volume2.08M
Market cap$354.52M
P/E (TTM)2.9x
P/S (TTM)2.7x
Div yield—
Key dataSep 18, 2026
Open
$7.60
From 52W high
−6.10%
Volume
2.08M
Market cap
$354.52M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
2.4x
P/E (TTM)
2.9x
RSI (14)
52.8
MomentumView details →
1D Return
+8.73%
YTD Return
+137.90%
SummaryUpdated Jun 1, 2026
Agenus Inc. (NASDAQ:AGEN) is a clinical-stage immuno-oncology biotechnology company founded in 1994 and headquartered in Lexington, Massachusetts. Originally incorporated as Antigenics Inc., the company changed its name to Agenus in January 2011. Agenus focuses on discovering and developing innovative cancer immunotherapies, with its lead program being the combination therapy of botensilimab and balstilimab (BOT/BAL) showing promising results in treating various solid tumors, particularly colorectal cancer. The company went public in February 2000 and has built a comprehensive pipeline of immuno-oncology treatments while also developing proprietary antibody discovery platforms.
Similar companies
Latest newsMore news →
Agenus Inc. announced that a poster on botensilimab plus balstilimab in recurrent ovarian cancer was accepted for presentation at the IGCS Annual Global Meeting in Montreal, Canada, on October 1-3, 2026.10d agoAgenus announced the peer-reviewed publication of updated results from the Phase 2 NEST trial of neoadjuvant botensilimab and balstilimab in resectable colon cancer, reporting deep pathologic responses and no observed recurrences.25d agoAgenus Inc. amended and restated its existing promissory note with Ocean 1181 LLC, extending the maturity to November 30, 2029, maintaining a 13.0% annual interest rate, and adding a $247,500 extension fee, half of which is payable in common stock.34d ago